Tech Company Financing Transactions
Vedanta Biosciences Funding Round
Vedanta Biosciences, based in Cambridge, secured $27 million from Bill & Melinda Gates Foundation, Bristol-Myers Squibb and INVESCO Private Capital.
Transaction Overview
Company Name
Announced On
12/24/2018
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Vedanta Biosciences' pipeline of microbiome-derived product candidates, including a Phase 1/2 study of VE416 in food allergy, a Phase 1b/2 study of VE800 and Opdivo (nivolumab) in advanced or metastatic cancers, and the recently initiated Phase 2 study of VE303 in recurrent Clostridium difficile infection (rCDI).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
19 Blackstone St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/24/2018: Dolls Kill venture capital transaction
Next: 12/24/2018: CherryHome venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs